All In Biotech

Drug Trial Radar · NCT03427125

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

A 26-Wk, Phase 3, Open Label (OL) Study With a 12-Wk, Placebo-Controlled, Randomized Withdrawal Period and an OL Safety Extension to Evaluate the Safety and Efficacy of Tenapanor to Treat Hyperphosphatemia in CKD Patients on Dialysis

Last checked: Nov 19, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,559 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,559

Actual

Start

Jan 8, 2018

Primary completion

Nov 15, 2019

Study completion Feb 27, 2020

Sponsor

Lead sponsor
ArdelyxIndustry
Sponsor type
Industry
First posted
Feb 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3, 26-week, open label study with a 12-week, placebo-controlled, randomized withdrawal period followed by an open label long term safety extension will evaluate the safety and efficacy of tenapanor to treat hyperphosphatemia in end-stage renal disease (ESRD) on hemodialysis and peritoneal dialysis.

Conditions

  • Hyperphosphatemia

Interventions

  • TenapanorDrug

    Active Drug

  • PlaceboDrug

    Inactive Drug

  • Sevelamer CarbonateDrug

    Active control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder PopulationTime frame: 12 weeks (randomized withdrawal period)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site 529

    The Bronx, New York

  • Wake Forest School of Medicine

    Winston-Salem, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.